Takeaway

• In previously treated patients with metastatic castration-resistant prostate cancer, no significant difference in health-related QoL and pain is reported with olaparib plus abiraterone compared with placebo plus abiraterone.

Why this matters

• These QoL data will help support informed decision making by patients and clinicians.

Study design

• A double-blind, randomized, placebo-controlled, phase...